Catalogo dei prodotti della ricerca

SANTINI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.676
EU - Europa 2.608
AS - Asia 1.786
AF - Africa 34
SA - Sud America 31
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.143
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.522
SG - Singapore 1.300
IT - Italia 1.088
SE - Svezia 784
IN - India 191
UA - Ucraina 151
CA - Canada 133
FI - Finlandia 127
DE - Germania 113
GB - Regno Unito 94
ID - Indonesia 90
CN - Cina 87
BG - Bulgaria 49
NL - Olanda 32
IE - Irlanda 31
HK - Hong Kong 30
TG - Togo 30
FR - Francia 25
KR - Corea 22
RO - Romania 21
BE - Belgio 20
MX - Messico 20
AT - Austria 18
AR - Argentina 16
CH - Svizzera 15
IR - Iran 13
ES - Italia 12
RU - Federazione Russa 11
JP - Giappone 10
TW - Taiwan 10
MY - Malesia 9
BR - Brasile 8
AM - Armenia 5
TR - Turchia 5
NZ - Nuova Zelanda 4
PH - Filippine 4
PL - Polonia 4
AU - Australia 3
CL - Cile 3
HU - Ungheria 3
PT - Portogallo 3
BD - Bangladesh 2
CO - Colombia 2
EE - Estonia 2
HR - Croazia 2
PE - Perù 2
PK - Pakistan 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BT - Bhutan 1
CI - Costa d'Avorio 1
CU - Cuba 1
EG - Egitto 1
EU - Europa 1
GR - Grecia 1
IL - Israele 1
JO - Giordania 1
KG - Kirghizistan 1
MA - Marocco 1
MK - Macedonia 1
NO - Norvegia 1
ZA - Sudafrica 1
Totale 10.143
Salva come PNG Salva come JPEG
Città #
Singapore 896
Princeton 700
Boston 666
Fairfield 553
Rome 461
Santa Clara 293
Woodbridge 279
Ashburn 271
Chandler 228
Houston 226
Wilmington 197
Cambridge 196
Andover 191
Seattle 176
Millbury 110
Stockholm 109
Toronto 106
San Paolo di Civitate 95
Ann Arbor 94
Jakarta 85
Helsinki 75
Milan 70
Lawrence 68
San Diego 65
Sofia 49
Plano 48
New York 47
Beijing 40
Jacksonville 36
San Mateo 34
Dearborn 32
Lomé 30
Dublin 29
Boardman 26
London 21
Los Angeles 16
Brussels 15
Hong Kong 15
Ottawa 15
Bern 13
Naples 13
Springfield 13
Federal 12
Norwalk 12
Vienna 12
Bremen 11
Des Moines 11
Florence 11
Groningen 11
Lappeenranta 11
Prineville 11
Turin 11
Bühl 10
Laurel 9
Fort Worth 8
Fremont 8
Mexico City 8
Yeonsu-gu 8
Amsterdam 7
Cassano Allo Ionio 7
New Delhi 7
Perugia 7
Rizziconi 7
Taipei 7
Verona 7
Genoa 6
Kolkata 6
Paris 6
Sandston 6
Trumbull 6
Chicago 5
Hasselt 5
Hefei 5
Munich 5
Phoenix 5
Portland 5
Barcelona 4
Berlin 4
Brooklyn 4
Bucharest 4
Buenos Aires 4
Catania 4
Dallas 4
Fenile 4
Frankfurt am Main 4
Gainesville 4
Goyang-si 4
Henderson 4
Istanbul 4
Kilburn 4
Leawood 4
Madrid 4
Mannheim 4
Mantova 4
Montréal 4
Seriate 4
Torino 4
Wappingers Falls 4
Albano Laziale 3
Auckland 3
Totale 7.069
Salva come PNG Salva come JPEG
Nome #
H2020 and beyond: skip discrepancy between theory and practice of personalized medicine. A position paper by the italian society of personalized medicine 125
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience 120
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 106
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 99
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study 99
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. 93
Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer 91
Pembrolizumab for the treatment of non-small-cell lung cancer 86
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. a “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy 86
Prognostic role of circulating tumor cell trajectories in metastatic colorectal cancer 85
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety 85
Increased apoptosis in remote non-infarcted myocardium in multivessel coronary disease 83
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome 83
Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. 82
Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction 81
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study 80
Targeting bone metastatic cancer. Role of the mTOR pathway 80
No evidence of association between psychological distress and pain relief in patients with bone metastases from castration‐resistant prostate cancer treated with 223Radium 80
Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors 78
Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study 78
Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria? 77
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. 77
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab. a real-life multicentre study 77
Ischemia and apoptosis in an animal model of permanent infarct-related artery occlusion 76
Myocardial expression of survivin, an apoptosis inhibitor, in aging and heart failure. An experimental study in the spontaneously hypertensive rat 73
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study 71
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 71
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials. 70
Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates 69
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients. A multicenter Italian experience 67
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma 66
Cyclo-oxygenase-2 (COX2) inhibition reduces apoptosis in acute myocardial infarction. 65
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer. The multicenter “SLAVE” study 65
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis 64
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 64
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies 63
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 63
Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. 62
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO 62
Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression ≥ 50% and their relationship with clinical outcomes 62
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 62
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line 61
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 61
Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients 59
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 59
The antineoplastic role of bisphosphonates: from basic research to clinical evidence 53
Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient 53
Immunotherapy for colorectal cancer: where are we heading? 52
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective analysis of progression-free (PFS) and overall survival (OS) in the “Real Life” 52
Effects of cabozantinib on bone turnover markers in patients with metastatic renal cell carcinoma 52
Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid 51
Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian managed access program 51
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis 51
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors. the multicenter FAMI-L1 study 50
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 50
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: the multicenter retrospective CLARITY study 49
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 49
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 47
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice 46
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors. A multicentre analysis of immune-related adverse events 45
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study 44
A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy 44
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 44
Large−scale profiling of extracellular vesicles identified miR−625−5p as a novel biomarker of immunotherapy response in advanced non−small−cell lung cancer patients 43
Trattamento precauzionale del carcinoma mammario in età geriatrica. 42
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 42
ADJUVANT TREATMENT FOR BREAST CANCER IN THE ELDERLY 41
Usefulness of the determination of 5NU together with CA 19-9 in the diagnosis and monitoring of dyskaryokinetic liver diseases 41
A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors 40
Hypoxia inducible factor-1 expession mediates myocardial response to ischemia late after acute myocardial infarction. 40
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 40
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer 39
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study 39
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients. a multicenter study of clinicians’ attitudes 38
Tolerability of raltitrexed ('Tomudex') in elderly patients with colorectal cancer 38
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis 37
Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with Nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective multicenter study 37
Metastatic renal cell carcinoma management: from molecular mechanism to clinical practice 37
HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer 36
Anestesia e malattie non comuni 36
Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment 34
Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments 34
Bladder Cancer. Andrea Tubaro, Daniele Santini, Cosimo De Nunzio, Alice Zoccoli, Michele Iuliano. In Biotargets of cancer in current clinical practice. M Bologna Editors. Springer edition. 2012 34
The value of the multidisciplinary team in metastatic renal cell carcinoma: paving the way for precision medicine in toxicities management 34
Circulating immunosuppression correlates with worse clinical outcome in head and neck cancer patients undergoing immunotherapy treatment 33
Treg/CD137+ T cell balance as a novel biomarker of survival in advanced non-addicted NSCLC patients treated with immunotherapy as first-line 33
Her2-positive early brest cancer in the pre-Trastuzumab and Trastuzumab eras: a triple positive subgroup analysis of a multicenter retrospective study 33
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 33
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 31
Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis 30
Standardization of body composition status in patients with advanced urothelial tumors: the role of a CT-based aI-powered software for the assessment of sarcopenia and patient outcome correlation 30
Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel 29
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 29
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials 28
Evaluation of efficacy of ALK inhibitors according to body mass index in ALK rearranged NSCLC patients—A retrospective observational study 28
Network approach in liquidomics landscape 26
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions. Is there any difference? 26
The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients 25
Tumor markers in colorectal cancer 25
Cyclooxygenase-2 overexpresion is associated with a poor outcome in resected ampullary cancer patients. 24
Totale 5.614
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.391
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.391
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020789 0 0 0 0 116 118 128 130 116 97 42 42
2020/2021559 52 47 19 27 14 31 34 61 42 84 59 89
2021/20222.422 7 35 88 40 123 29 27 104 73 64 180 1.652
2022/20233.005 1.206 318 134 135 396 368 68 86 176 28 64 26
2023/20242.143 87 148 72 116 136 154 58 133 81 331 294 533
2024/20251.984 199 267 843 329 346 0 0 0 0 0 0 0
Totale 11.744